Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled study of satralizumab in moderate-to-severe thyroid eye disease
CTR20232982Phase 3Active
- Sponsor
- Roche
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of satralizumab in Graves Orbitopathy (GO), sponsored by Roche. Started Nov 2023; status: active.
02
Drugs
satralizumab
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on CTR20232982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232982.